CT-Don 12.5 Tablet

CT-Don 12.5 Tablet contains chlorthalidone, a sulphonamide-derived thiazide-like diuretic with a pharmacological profile similar to conventional thiazide diuretics but with a significantly longer duration of action due to its extensive binding to carbonic anhydrase in erythrocytes.

Chlorthalidone inhibits the sodium-chloride cotransporter in the distal convoluted tubule of the kidney, reducing tubular reabsorption of sodium and chloride. This increases urinary sodium and water excretion, reducing plasma volume, venous return, and cardiac output, thereby lowering blood pressure. With continued use, peripheral vascular resistance also decreases, contributing to sustained antihypertensive effect.

Compared to hydrochlorothiazide, chlorthalidone has a half-life of approximately 40 to 60 hours versus 6 to 15 hours, providing more sustained and consistent 24-hour blood pressure control including nocturnal and early-morning hours when cardiovascular events are most common. Large outcome trials have demonstrated superior cardiovascular risk reduction with chlorthalidone compared to other antihypertensive agents.

Chlorthalidone also has mild carbonic anhydrase inhibitory activity which contributes to its prolonged action and mild reduction in intraocular pressure.

The uses of CT-Don 12.5 Tablet are as follows:

Hypertension

CT-Don 12.5 Tablet is used as first-line or adjunctive antihypertensive therapy in adults with elevated blood pressure.

Oedema in Heart Failure

It reduces fluid retention and peripheral oedema by promoting sodium and water excretion.

Oedema in Renal Disease

It is used to manage fluid overload in patients with renal conditions associated with sodium retention.

Oedema in Hepatic Cirrhosis

It is used to reduce ascites and peripheral oedema in cirrhotic patients under medical supervision.

Isolated Systolic Hypertension

Particularly well-evidenced for reducing systolic blood pressure and cardiovascular event risk in elderly hypertensive patients.

Combination Antihypertensive Therapy

Widely used alongside ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers for additive blood pressure control.

Here are the benefits of CT-Don 12.5 Tablet:

• Prolonged Duration of Action: A half-life of 40 to 60 hours provides more consistent 24-hour blood pressure control than shorter-acting thiazides.

• Superior Cardiovascular Outcomes: Large clinical trials demonstrate chlorthalidone's superiority in reducing stroke, myocardial infarction, and heart failure compared to many other antihypertensives.

• Effective in Isolated Systolic Hypertension: Particularly well-studied in elderly patients where systolic pressure reduction reduces stroke and cardiovascular event risk.

• Reduces Fluid Overload: Diuretic action effectively reduces oedema and fluid retention across multiple oedematous states.

• Once-Daily Convenience: Long half-life supports reliable once-daily dosing improving treatment adherence.

Like all medicines, CT-Don 12.5 Tablet may cause side effects in some individuals.

Common Side Effects:

• Hypokalaemia: Increased urinary potassium excretion may lower serum potassium, requiring monitoring.

• Increased Urination: Expected diuretic effect, particularly pronounced in the first weeks of treatment.

• Dizziness or Light-Headedness: Particularly on standing, due to blood pressure reduction and volume depletion.

• Muscle Cramps: Electrolyte disturbances may cause muscle discomfort.

Uncommon Side Effects:

• Hyponatraemia: Low sodium levels may occur, particularly in elderly patients.

• Hyperuricaemia: Chlorthalidone reduces uric acid excretion, potentially precipitating gout in susceptible individuals.

• Impaired Glucose Tolerance: Mild glycaemic effects may occur particularly at higher doses.

• Headache: Mild headache may develop during early treatment.

Serious Side Effects (Require Immediate Medical Attention):

• Severe Electrolyte Disturbance: Marked hypokalaemia or hyponatraemia may cause cardiac arrhythmias or neurological symptoms.

• QT Interval Prolongation: Hypokalaemia induced by chlorthalidone may increase arrhythmia risk in susceptible patients.

• Acute Renal Impairment: Excessive volume depletion may reduce renal perfusion and precipitate acute kidney injury.

• Severe Allergic Reaction: Swelling of the face, lips, or throat with difficulty breathing requires urgent medical care.

Always consult your doctor if side effects persist or worsen.

To ensure safe use:

• Use exactly as prescribed by your doctor.

• Usually taken orally once daily in the morning to minimise nocturnal diuresis.

• Take at the same time each day for consistent blood pressure control.

• Swallow tablets whole unless otherwise instructed.

• Do not discontinue without consulting your doctor.

Chlorthalidone inhibits the sodium-chloride cotransporter (NCC) in the apical membrane of the distal convoluted tubule cells. This prevents reabsorption of sodium and chloride ions from the tubular lumen into the bloodstream, increasing their concentration in the tubular fluid and promoting osmotic water retention in the tubule.

The resulting increase in urinary sodium, chloride, and water excretion reduces circulating plasma volume, venous return, and cardiac preload. Reduced cardiac output initially accounts for blood pressure lowering. With continued treatment, plasma volume partially normalises but peripheral vascular resistance decreases, sustaining the antihypertensive effect through a second mechanism.

Chlorthalidone's prolonged action compared to hydrochlorothiazide is attributed to its high degree of binding to carbonic anhydrase in erythrocytes, creating a circulating depot that slowly releases the drug. Mild carbonic anhydrase inhibitory activity also contributes to reduced bicarbonate reabsorption and modest additional diuretic effect.

A few practical measures can help improve treatment outcomes and ensure safe use of CT-Don 12.5 Tablet:

• Take in the morning: Morning dosing ensures the diuretic effect occurs during waking hours, reducing nocturnal sleep disruption from increased urination.

• Monitor electrolytes regularly: Periodic blood tests to check potassium and sodium levels are important during treatment, particularly in elderly patients and those on other medicines.

• Rise slowly from lying or sitting: Postural hypotension is more likely during early treatment and after dose adjustment; changing position slowly reduces fall risk.

• Maintain adequate fluid intake: Avoid excessive fluid restriction which may compound the diuretic effect and worsen electrolyte disturbance.

• Inform your doctor of gout history: Chlorthalidone reduces uric acid excretion and may precipitate gout attacks in susceptible individuals.

Proper storage is important to maintain the stability and effectiveness of CT-Don 12.5 Tablet:

• Store at room temperature: Keep away from heat, moisture, and direct sunlight.

• Keep in original packaging: Protects tablets from humidity and light.

• Keep out of reach of children: Store safely to prevent accidental ingestion.

• Check expiry before use: Do not use after the expiry date printed on the packaging.

CT-Don 12.5 Tablet may generally be taken without strict dietary restrictions. However:

• Avoid excessive alcohol: Enhances blood pressure lowering and increases dizziness and dehydration risk.

• Maintain adequate dietary potassium: Foods rich in potassium such as bananas, oranges, and leafy vegetables help offset urinary potassium loss.

• Reduce dietary sodium: A low-sodium diet complements the antihypertensive effect of chlorthalidone.

CT-Don 12.5 Tablet may interact with the following medicines:

• Lithium: Chlorthalidone reduces lithium excretion, raising the risk of lithium toxicity. Close monitoring is required.

• NSAIDs: May reduce the antihypertensive and diuretic effects of chlorthalidone and increase the risk of renal impairment.

• QT-Prolonging Medicines: Hypokalaemia induced by chlorthalidone may potentiate the arrhythmia risk of QT-prolonging agents.

• Potassium-Depleting Medicines: Concurrent use of corticosteroids or loop diuretics may compound hypokalaemia.

• Antidiabetic Medicines: Chlorthalidone may impair glycaemic control, potentially requiring dose adjustments in diabetic patients.

• Digoxin: Chlorthalidone-induced hypokalaemia increases the risk of digoxin toxicity and arrhythmias; electrolyte monitoring is essential.

CT-Don 12.5 Tablet should be used carefully in the following conditions:

• Hypokalaemia or Hyponatraemia: Pre-existing electrolyte disturbances may be worsened by chlorthalidone.

• Gout: Chlorthalidone reduces uric acid excretion and may precipitate gout attacks in susceptible individuals.

• Diabetes Mellitus: May impair glucose tolerance, particularly at higher doses; blood glucose monitoring is advisable.

• Hyperaldosteronism: Chlorthalidone may be less effective in primary hyperaldosteronism due to aldosterone-driven sodium retention.

• Systemic Lupus Erythematosus: Thiazide-like diuretics may exacerbate or activate lupus in susceptible individuals.

Usually taken as a single oral dose once daily in the morning as directed by your doctor. Dose depends on the indication and degree of blood pressure or fluid control required.

If a dose is missed, take it as soon as remembered. Do not double the dose to make up for a missed one.